Pediatrix Medical Group (MD) director receives 472 restricted shares in equity grant

Rhea-AI Filing Summary

Linynsky Laura A reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group director Laura A. Linynsky received a grant of 472 restricted shares of common stock on August 12, 2026 under the company’s Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to her annual equity award. The restricted shares were valued at $26.50 per share for reporting purposes and will vest on May 7, 2027. Following this grant, Linynsky directly holds 39,900 shares of Pediatrix Medical Group common stock.

Insider Trade Summary

Net Buyer: 472 shares

Net Buy 1 txn

Insider Linynsky Laura A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	472	$26.50	$13K

Holdings After Transaction: Common Stock — 39,900 shares (Direct)

Footnotes (1)

1. F1. Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to the annual equity award. Shares will vest on May 7, 2027.

Key Figures

Restricted shares granted: 472 shares Reported grant price: $26.50 per share Holdings after transaction: 39,900 shares +1 more

4 metrics

Restricted shares granted 472 shares Equity award to director Laura A. Linynsky on August 12, 2026

Reported grant price $26.50 per share Value used for the restricted share grant reported on Form 4

Holdings after transaction 39,900 shares Total common stock directly held by Laura A. Linynsky after the grant

Vesting date May 7, 2027 Date when the 472 restricted shares are scheduled to vest

Key Terms

Restricted shares, Incentive Compensation Plan, annual equity award

3 terms

Restricted shares financial

"Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

Incentive Compensation Plan financial

"granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan"

An incentive compensation plan is a formal program that rewards employees and executives with bonuses, stock, or other payments tied to specific performance goals—such as revenue, profit, productivity, or long‑term share price. Investors watch these plans because they shape how leaders make decisions and take risks; like paying a coach by wins rather than effort, well‑designed plans can drive sustainable growth while poor designs can encourage short‑term behaviors that harm shareholder value.

annual equity award financial

"reflecting an increase to the annual equity award. Shares will vest on May 7, 2027."

FAQ

What did Pediatrix Medical Group (MD) disclose about Laura A. Linynsky’s latest stock grant?

Pediatrix Medical Group reported that director Laura A. Linynsky received 472 restricted shares of common stock on August 12, 2026. The grant was made under the company’s 2008 Incentive Compensation Plan and reflects an increase to her annual equity award.

At what price were the new restricted shares for MD’s director Laura A. Linynsky reported?

The 472 restricted shares granted to Laura A. Linynsky were reported at $26.50 per share. This price is used for Form 4 reporting and does not necessarily represent a market transaction, as the shares were granted as equity compensation.

When will Laura A. Linynsky’s new restricted shares in Pediatrix Medical Group (MD) vest?

The newly granted restricted shares to Laura A. Linynsky will vest on May 7, 2027. Until vesting, the shares are subject to the plan’s restrictions, after which they are expected to become fully owned, subject to any plan terms.

How many Pediatrix Medical Group (MD) shares does Laura A. Linynsky hold after this transaction?

After the August 12, 2026 grant, Laura A. Linynsky directly holds 39,900 shares of Pediatrix Medical Group common stock. This total includes the newly awarded 472 restricted shares reported in the Form 4 filing.

Under which plan were the new restricted shares for MD director Laura A. Linynsky granted?

The 472 restricted shares for Laura A. Linynsky were granted under Pediatrix Medical Group’s Second Amended and Restated 2008 Incentive Compensation Plan. The filing notes that this grant reflects an increase to her annual equity award under the plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 05:01 PM Accepted by SEC EDGAR 08/14/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Linynsky Laura A

(Last) (First) (Middle)

1301 CONCORD TERRACE

(Street)

SUNRISE FLORIDA 33323

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		A(1)		472	A	$26.5	39,900	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted shares granted pursuant to Issuer's Second Amended and Restated 2008 Incentive Compensation Plan, reflecting an increase to the annual equity award. Shares will vest on May 7, 2027.

	/s/ David Haddock, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)